NASDAQ:ATNX

Athenex (ATNX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.20
$1.52
52-Week Range
N/A
Volume
1.88 million shs
Average Volume
194,316 shs
Market Capitalization
$1.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATNX stock logo

About Athenex Stock (NASDAQ:ATNX)

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

ATNX Stock News Headlines

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Athenex (NASDAQ: ATNX)
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Athenex files Chapter 11
Athenex Files For Chapter 11 Bankruptcy
Athenex (ATNX) Upgraded to Buy: Here's Why
Athenex Announces a Reverse Stock Split
Athenex Announces MHRA Decision on Oral Paclitaxel
See More Headlines
Receive ATNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATNX
Fax
N/A
Employees
652
Year Founded
N/A

Profitability

Net Income
$-103,430,000.00
Pretax Margin
-95.92%

Debt

Sales & Book Value

Annual Sales
$102.82 million
Book Value
($3.07) per share

Miscellaneous

Free Float
7,866,000
Market Cap
$1.76 million
Optionable
Optionable
Beta
1.36
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Yiu Nam Lau
    Chairman & Chief Executive Officer
  • Jeff Yordon
    COO & President-Athenex Pharmaceutical Division
  • Joe Annoni
    Chief Financial Officer
  • Darrel P. Cohen
    Chief Medical Officer
  • William Zuo
    President-China Operations

ATNX Stock Analysis - Frequently Asked Questions

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The company had revenue of $32.30 million for the quarter, compared to analyst estimates of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period in the previous year, the company posted ($0.44) earnings per share.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

When did Athenex IPO?

Athenex (ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

This page (NASDAQ:ATNX) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners